多发性骨髓瘤血栓形成机制的研究现状

doi:10.3969/j.issn.1006-7795.2014.05.011

摘要/Abstract

摘要：

多发性骨髓瘤（multiple myeloma，MM）是一种浆细胞异常增生的恶性肿瘤。MM患者血栓栓塞事件发生率明显高于其他实体瘤，且血栓的发展影响患者预后及远期生存率。MM患者血栓的形成原因除了包括疾病本身的合并症、瘤细胞因素，相关治疗药物也是一个重要的因素。因此了解骨髓瘤患者血栓形成相关机制及预防非常重要。

关键词: 多发性骨髓瘤, 血栓, 机制

Abstract:

Multiple myeloma (MM) is a malignant tumor with abnormal proliferation of plasma cells. Individuals with MM have a higher risk of thrombosis than other solid tumors, and the development of thrombosis would impact the prognosis and long-term survival. The chemotherapy played an important role in thrombosis in MM except for the complications of the disease itself and the factors of tumor cells. Therefore, it is very important to understand the mechanisms and prevention of thrombosis in MM.

Key words: multiple myeloma, thrombosis, mechanism

中图分类号:

杨艳, 杨林花. 多发性骨髓瘤血栓形成机制的研究现状[J]. 首都医科大学学报, 2014, 35(5): 581-584.

Yang Yan, Yang Linhua. Present status of studies on mechanism of thrombosis in multiple myeloma[J]. Journal of Capital Medical University, 2014, 35(5): 581-584.

参考文献

[1] Lee A Y, Levine M N. Venous thromboembolism and cancer: Risks and outcomes [J]. Circulation,2003,107(23 Supple 1):117-121.
[2] Musallam K M, Dahdaleh F S, Shamseddine A l, et al. Incidence and prophylaxis of venous thromboembolic events in multiplemveloma patients receiving immunomodulatory therapy [J]. Tbromb Res, 2009, 123(5):679-686.
[3] 杨林花.多发性骨髓瘤的凝血异常[J]. 临床血液学杂志,2012,25(7):414-417.
[4] Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone [J].J Clin Oncol, 2010,28(1):132-135.
[5] Smith R A, Cokkinides V, Eyre H J. American Cancer So ciety guidelines for the early detection of cancer, 2006[J].CA Cancer J Clin,2006,56(1): 11-25.
[6] Shimizu K, Itoh J. A possible link between Trousseau's syndrome and tissue factor producing plasma cells [J]. Am J Hematol,2009, 84(6): 382-385.
[7] 侯彦飞,杨林花,任方刚,等.组织因子微粒在多发性骨髓瘤中的表达及临床意义[J].临床血液学杂志,2014,27(7):573-576.
[8] Auwerda J J, Sonneveld P, de Maat M P, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J]. Haematologica, 2007, 92(2): 279-280.
[9] 白洁,薛艳萍,许现辉,等.骨髓增殖性肿瘤患者活化蛋白C抵抗和凝血功能异常研究[J].中华血液学杂志,2011,32(3): 187-190.
[10] De Lucia D, De Vita F, Orditura M, et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C [J]. Tumori,1997, 83(6):948-952.
[11] Green D, Maliekel K, Sushko E, et al. Activated protein C resistance in cancer patients[J]. Haemostasis, 1997, 27(3): 112-118.
[12] Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism[J]. Am J Med, 2001, 110(2):91-96.
[13] Zangari M, Saghafifar F, Mehta P, et al. The blood coagulation mechanism in multiple myeloma [J]. Semin Thromb Hemost,2003, 29(3):275-282.
[14] Zangari M, Berno T, Zhan F, et al. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls[J]. Blood Coagul Fibrinolysis, 2011, 22(5): 420-423.
[15] Petropoulou A D, Gerotziafas G T, Samama M M, et al. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide [J].Thromb Res, 2008, 121(4): 493-497.
[16] Bolkun L, Piszcz J, Oleksiuk J, et al. Protein Z concentration in multiple myeloma patients[J]. Thromb Res, 2011, 128(5): 401-402.
[17] Barosi G, Merlini G, Billio A, et al. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma [J].Ann Hematol, 2012, 91(6): 875-888.
[18] Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later [J]. Blood, 2012, 120(5): 947-959.
[19] Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: current status and future potential [J].Am J Hematol, 2012, 87(12): 1089-1095.
[20] Gandhi A K, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function [J]. Curr Cancer Drug Targets, 2010, 10(2): 155-167.
[21] ElAccaoui R N, Shamseddeen W A, Taher A T.Thalidomide and thrombosis a meta-analysis [J]. Thromb Haemost, 2007, 97(6): 1031-1036.
[22] Görgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma[J]. Blood, 2010, 116(17): 3227-3237.
[23] Bolzoni M, Stori P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenviroment targeting the expression of adhesion molecules [J].Exp Hematol, 2013, 41(4): 387-397.
[24] Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J]. N Engl J Med, 2007, 357(21): 2123-2132.
[25] Rajkumar S V, Jacobus S, Callander N S, et al. Lenalidomid plus high-dose dexamethasone vsersus lenalidomide plus low-dose dexmethasone as initial therapy for newly diagnosed multiple myeloma;an open-label randomized controlled trial[J].Lancet Oncol,2010,11(1): 29-37.
[26] Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens [J]. Clin Lymphoma Myeloma Leuk,2011,11(2): 228-236.
[27] Shi D S, Smith M C, Campbell R A, et al. Proteasome function is required for platelet production [J]. J Clin Invest. 2014,124(9):3757-3766.
[28] Nayak L, Shi H, Atkins G B, et al. The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2) [J]. Blood, 2014, 123(24): 3828-3831.
[29] Balcik O S, Albayrak M, Uyar M E, et al. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma [J]. Blood Coaqul Fibrinolvsis, 2011, 22 (4): 260-263.
[30] Dri A P, Politou M, Gialeraki A, et al. Decreased incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosis [J]. Thromb Res,2013, 132(3): 400-401.
[31] 李迎春, 张嵘,王慧涵,等.沙利度胺联合环磷酰胺和地塞米松治疗复发难治多发性骨髓瘤[J]. 中国医科大学学报,2013,42(6):564-566.
[32] Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxapar in thromboprophylaxis in patients with multiple myeloma treated with thalidomide:a phase Ⅲ, open-label, randomized trial [J]. J Clin Oncol, 2011, 29(8): 986-993.
[33] Palumbo A,Rajkumar S V,Dimopoulos M A, et al.Prevention of thalidomide and lenalidomide-associated thrombosis in myeloma[J]. Leukemia, 2008, 22(2):414-423.